ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 533,66
-0,56%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. ImmunoGen Inc (IMGN)

  7. ImmunoGen Inc (IMGN) Actualités

IMGN

ImmunoGen (IMGN)

ImmunoGen Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:IMGN
DateHeureSourceTitreSymboleSociété
22/02/202422h15Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:IMGNImmunoGen Inc
14/02/202423h01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IMGNImmunoGen Inc
12/02/202422h48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMGNImmunoGen Inc
12/02/202422h33Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:IMGNImmunoGen Inc
12/02/202415h32Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:IMGNImmunoGen Inc
12/02/202413h52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMGNImmunoGen Inc
12/02/202413h37PR Newswire (US)AbbVie Completes Acquisition of ImmunoGenNASDAQ:IMGNImmunoGen Inc
05/02/202422h10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IMGNImmunoGen Inc
01/02/202422h30Business WireImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IMGNImmunoGen Inc
29/01/202423h01Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:IMGNImmunoGen Inc
12/01/202417h10PR Newswire (US)Kuehn Law Encourages PXD, IMGN, HA and ICVX Investors to Contact Law FirmNASDAQ:IMGNImmunoGen Inc
03/01/202400h10PR Newswire (US)Kuehn Law Encourages CERE, HA, IMGN, and WAVD Investors to Contact Law FirmNASDAQ:IMGNImmunoGen Inc
02/01/202422h26Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:IMGNImmunoGen Inc
21/12/202322h52Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:IMGNImmunoGen Inc
20/12/202301h00Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:IMGNImmunoGen Inc
10/12/202318h00Business WireImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASHNASDAQ:IMGNImmunoGen Inc
08/12/202312h23IH Market NewsApple Boosts Vietnam Production, Broadcom Revenue Miss, Stellantis Job Cuts – Latest UpdatesNASDAQ:IMGNImmunoGen Inc
05/12/202313h46Dow Jones NewsImmunogen Gets FDA Priority Review of Elahere Full ApprovalNASDAQ:IMGNImmunoGen Inc
30/11/202314h42Dow Jones NewsImmunoGen Shares Soar Premarket on Takeover by AbbVieNASDAQ:IMGNImmunoGen Inc
30/11/202314h13Dow Jones NewsAbbVie to Buy ImmunoGen for More Than $10 BillionNASDAQ:IMGNImmunoGen Inc
30/11/202313h30PR Newswire (US)AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor PortfolioNASDAQ:IMGNImmunoGen Inc
02/11/202321h30Business WireImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare ConferenceNASDAQ:IMGNImmunoGen Inc
02/11/202321h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMGNImmunoGen Inc
02/11/202311h30Business WireImmunoGen Reports Recent Progress and Third Quarter 2023 Financial ResultsNASDAQ:IMGNImmunoGen Inc
27/10/202312h30Business WireImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian CancerNASDAQ:IMGNImmunoGen Inc
23/10/202314h30PR Newswire (US)Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory BoardNASDAQ:IMGNImmunoGen Inc
19/10/202322h01Business WireImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating ResultsNASDAQ:IMGNImmunoGen Inc
28/09/202313h00Business WireELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian CancerNASDAQ:IMGNImmunoGen Inc
19/09/202323h37Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IMGNImmunoGen Inc
18/09/202312h30Business WireImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial OfficerNASDAQ:IMGNImmunoGen Inc
 Showing the most relevant articles for your search:NASDAQ:IMGN

Dernières Valeurs Consultées

NASDAQ
GOOGL
Alphabet
EU
BNP
BNP Paribas
EU
MC
Lvmh Moet Hennessy Louis...
EU
RNO
Renault
EU
CAP
Capgemini
EU
BN
Danone
FTSE
UKX
FTSE 100
EU
AI
Air Liquide
EU
CS
Axa
NYSE
MCD
McDonalds
EU
GLE
Societe Generale
EU
VIV
Vivendi
NASDAQ
MSFT
Microsoft
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés